Unraveling the Promise of RET Inhibitors in Precision Cancer Therapy by Targeting RET Mutations

• Published in: Journal of medicinal chemistry Vol. 67; no. 6; pp. 4346 - 4375
• Main Authors: Wang, Zi-Xuan, Li, Qing-Qing, Cai, Jiao, Wu, Jia-Zhen, Wang, Jing-Jing, Zhang, Meng-Yuan, Wang, Qing-Xin, Tong, Zhen-Jiang, Yang, Jin, Wei, Tian-Hua, Zhou, Yun, Dai, Wei-Chen, Ding, Ning, Leng, Xue-Jiao, Sun, Shan-Liang, Xue, Xin, Yu, Yan-Cheng, Yang, Ye, Li, Nian-Guang, Shi, Zhi-Hao
• Format: Journal Article
• Language: English
• Published: United States American Chemical Society 28.03.2024
• ISSN: 0022-2623; 1520-4804
• DOI: 10.1021/acs.jmedchem.3c02319

Over the past decades, the role of rearranged during transfection (RET) alterations in tumorigenesis has been firmly established. RET kinase inhibition is an essential therapeutic target in patients with RET-altered cancers. In clinical practice, initial efficacy can be achieved in patients through the utilization of multikinase inhibitors (MKIs) with RET inhibitory activity. However, the effectiveness of these MKIs is impeded by the adverse events associated with off-target effects. Recently, many RET-selective inhibitors, characterized by heightened specificity and potency, have been developed, representing a substantial breakthrough in the field of RET precision oncology. This Perspective focuses on the contemporary understanding of RET mutations, recent advancements in next-generation RET inhibitors, and the challenges associated with resistance to RET inhibitors. It provides valuable insights for the development of next-generation MKIs and selective RET inhibitors.